Neue Ära in der Behandlung des Diabetes mellitus bei der Katze

Bis vor Kurzem konnte Diabetes mellitus bei der Katze nur mittels Insulins behandelt werden, was mit 2-mal täglichen subkutanen Injektionen sowie einem engmaschigen Monitoring verbunden war. In diesem Artikel erfahren Sie mehr über SGLT2-Inhibitoren, eine neue Wirkstoffgruppe oraler Antidiabetika, die sowohl die Applikation als auch das Monitoring erleichtert.

Publikationsverlauf

Artikel online veröffentlicht:
23. August 2024

• Literatur

• 1 Niessen SJM, Voth R, Kroh C, Hennings L. Once-daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as standalone therapy compared to insulin injection therapy in diabetic cats. Research Communications of the 32nd ECVIM-CA Congress, 2022: Göteborg (Schweden), 1. – 3. September.
• 2 Niessen SJM, Kooistra HS, Forcada Y. et al. Efficacy and Safety of Once-Daily Oral Sodium-Glucose Co-Transporter-2-Inhibitor Velagliflozin Compared to Twice-Daily Insulin Injection Therapy in Diabetic Cats. J Vet Intern Med 2024; [online ahead of print].
• 3 Behrend EN, Ward C, Chukwu V. et al. Velagliflozin, an SGLT-2-inhibitor, as once-daily, oral solution, stand-alone therapy for feline diabetes mellitus. ACVIM Forum Research Report Program, 2023.
• 4 Boehringer Ingelheim Vetmedica. Gebrauchsinformation Senvelgo. Im Internet: https://www.vetmedica.de/produkte-tierarzt/Katze/senvelgo15mgml/7970 Stand: Juni 2024
• 5 EsSayed NA, Aleppo G, Aroda VR. et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes–2023. Diabetes Care 2023; 46 (Suppl. 1) S140-S157
• 6 Nelson RW, Griffey SM, Feldman EC, Ford SL. Transient clinical diabetes mellitus in cats: 10 cases (1989–1991). J Vet Intern Med 1999; 13 (01) 28-35
• 7 Tschuor F, Zini E, Schellenberg S. et al. Remission of Diabetes Mellitus in Cats Cannot be Predicted by the Arginine Stimulation Test. J Vet Intern Med 2011; 25 (01) 83-89
• 8 Hadd MJ, Bienhoff SE, Little SE. et al. Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. J Vet Intern Med 2023; 37 (03) 915-924
• 9 Boehringer Ingelheim Vetmedica. Senvelgo – Leitfaden Patientenmanagement. Im Internet: https://www.vetmedica.de/bbgkgesjwuwuwfjrgjdjadawfegedfess.pdfx Stand: Juni 2024
• 10 Ceriello A, Prattichizzo F, Phillip M. et al. Glycaemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol 2022; 10 (01) 75-84
• 11 Roomp K, Rand J. Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine. J Feline Med Surg 2009; 11 (08) 668-682
• 12 Schramm F, Weiß M, Dahlem D. Beta-Hydroxybutyrat-Messung mit dem GlucoMen^®LX Plus zur Diagnose der diabetischen Ketoazidose bei Hunden und Katzen. Beta-hydroxybutyrate measurements with the GlucoMen^®LX Plus in the diagnosis of diabetic ketoacidosis in dogs and cats. Tierarztl Prax Ausg K Kleintiere Heimtiere 2020; 48 (05) 322-328
• 13 Weingart C, Lotz F, Kohn B. Measurement of β-hydroxybutyrate in cats with nonketotic diabetes mellitus, diabetic ketosis, and diabetic ketoacidosis. J Vet Diagn Invest 2012; 24 (02) 295-300
• 14 Benedict SL, Mahony OM, McKee T, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus. Can J Vet Res 2022; 86 (01) 52-58
• 15 Box JR, Oyama MA, Mosenco AS, Hess RS. Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs. J Vet Intern Med 2024; 38 (03) 1353-1358